Contact
searchSearch
HMP Global
Login

Tenosynovial Giant Cell Tumor Excellence Forum

Tenosynovial Giant Cell Tumor
Excellence Forum
Leaders in the field sharing authoritative insights and institutional best practices.

Interview
Experts Uncover Atypical Gene Fusions in TGCT Via Molecular Profiling
01/20/2020
George Jour, MD, discusses the findings of a study involving the molecular profiling of atypical TGCT.
George Jour, MD, discusses the findings of a study involving the molecular profiling of atypical TGCT.
George Jour, MD, discusses the...
01/20/2020
Oncology
News
DCC-3014 Well-Tolerated, Active in Patients With Diffuse-Type TGCT
12/12/2019
Findings from a phase 1 clinical trial demonstrate that DCC-3014 is active and generally well-tolerated in patients with diffuse-type TGCT.
Findings from a phase 1 clinical trial demonstrate that DCC-3014 is active and generally well-tolerated in patients with diffuse-type TGCT.
Findings from a phase 1 clinical...
12/12/2019
Oncology
Podcasts
Evolution of the Treatment Landscape for Tenosynovial Giant Cell Tumors
11/21/2019
Jonathan Trent, MD, PhD, discusses the evolution of the current treatment landscape for TGCT.
Jonathan Trent, MD, PhD, discusses the evolution of the current treatment landscape for TGCT.
Jonathan Trent, MD, PhD,...
11/21/2019
Oncology
Podcasts
Pexidartinib Demonstrates Great Tumor Response in Tenosynovial Giant Cell Tumors
11/13/2019
Brian Van Tine, MD, discusses results from the ENLIVEN trial, which evaluated pexidartinib, a CSF1 receptor inhibitor, in patients with TGCT.
Brian Van Tine, MD, discusses results from the ENLIVEN trial, which evaluated pexidartinib, a CSF1 receptor inhibitor, in patients with TGCT.
Brian Van Tine, MD, discusses...
11/13/2019
Oncology
News
Imatinib Mesylate Demonstrates Long-Term Efficacy in TGCT
10/20/2019
Results from a retrospective study confirm the long-term efficacy of imatinib mesylate in patients with advanced TGCT.
Results from a retrospective study confirm the long-term efficacy of imatinib mesylate in patients with advanced TGCT.
Results from a retrospective...
10/20/2019
Oncology
Commentary
Surgery Yields High Risk for Recurrence, Complications in Patients With TGCTs
10/08/2019
Surgery is not a definitive treatment for every patient with diffuse-type TGCTs.
Surgery is not a definitive treatment for every patient with diffuse-type TGCTs.
Surgery is not a definitive...
10/08/2019
Oncology
Commentary
FDA Approves Pexidartinib for Symptomatic TGCTs
10/08/2019
The FDA has approved pexidartinib to treat certain adults with symptomatic TGCTs.
The FDA has approved pexidartinib to treat certain adults with symptomatic TGCTs.
The FDA has approved...
10/08/2019
Oncology
Pexidartinib Improves Overall Response in Patients with TGCT
09/23/2019
Findings from the ENLIVEN trial suggest pexidartinib as a potential therapy option for tenosynovial giant cell tumor (TGCT) in patients not amenable to surgical resection.
Findings from the ENLIVEN trial suggest pexidartinib as a potential therapy option for tenosynovial giant cell tumor (TGCT) in patients not amenable to surgical resection.
Findings from the ENLIVEN trial...
09/23/2019
Oncology

Section Editor

Robert Maki, MD, PhD
Northwell Health Cancer
Center Institute, New York

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use